-+ 0.00%
-+ 0.00%
-+ 0.00%

Valbiotis says REVERSE-IT trial results for Totum•63 published in Nature Communications

PUBT·07/22/2026 15:40:45
Listen to the news
Valbiotis says REVERSE-IT trial results for Totum•63 published in Nature Communications
  • Valbiotis flagged publication of REVERSE-IT clinical trial results for Totum•63 in Nature Communications as a major scientific milestone.
  • Randomized, placebo-controlled 24-week study across 52 European centers enrolled 636 adults with prediabetes or newly diagnosed type 2 diabetes.
  • Trial met its primary endpoint, showing a significant reduction in fasting blood glucose at 6 months versus placebo.
  • Data also showed favorable shifts in selected cardiometabolic markers, including HbA1c, insulin resistance, weight, lipids.
  • Totum•63 showed no specific safety signal; reported adherence reached 97% across study groups.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valbiotis SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2370142_fr) on July 22, 2026, and is solely responsible for the information contained therein.